Who owns Celldex Therapeutics?

Key details on Celldex Therapeutics (Ticker: CLDX)

Who owns Celldex Therapeutics?

Is CLDX a good stock to own? Find out who bought Celldex Therapeutics, who sold Celldex Therapeutics (CLDX) stock, and who holds a large position in Celldex Therapeutics.

Fund Name Number of Shares Share Valuation As Of
FMR 12.16M $294.33M Dec. 31, 2013
Franklin Resources 7.93M $191.99M Dec. 31, 2013
Vanguard 4.97M $120.38M Dec. 31, 2013
Jennison Associates 3.98M $96.40M Dec. 31, 2013
OppenheimerFunds 3.76M $91.05M Dec. 31, 2013
S.A.C. Capital Advisors 3.51M $84.89M Dec. 31, 2013
BlackRock Fund Advisors 3.15M $76.24M Dec. 31, 2013
Ridgeback Capital Investments 2.86M $18.02M Sept. 30, 2012
HealthCor Management 2.50M $8.88M June 30, 2011
BlackRock Institutional Trust Company, N.A. 2.39M $57.80M Dec. 31, 2013
Sectoral Asset Management 2.23M $53.93M Dec. 31, 2013
TimesSquare Capital Management 2.20M $53.32M Dec. 31, 2013
Columbus Circle Investors 2.19M $53.00M Dec. 31, 2013
STATE STREET CORPORATION 2.18M $52.80M Dec. 31, 2013
Columbia Wanger Asset Management 1.67M $40.45M Dec. 31, 2013
Wellington Management Company 1.62M $25.26M June 30, 2013
HealthCor Management 1.45M $22.63M June 30, 2013
SUSQUEHANNA INTERNATIONAL 1.34M $32.56M Dec. 31, 2013
OrbiMed Advisors 1.31M $31.73M Dec. 31, 2013
NORTHERN TRUST 1.28M $30.90M Dec. 31, 2013
BlackRock Advisors 1.21M $42.85M Sept. 30, 2013
DIMENSIONAL FUND ADVISORS 1.14M $27.48M Dec. 31, 2013
LORD, ABBETT & CO 1.01M $24.54M Dec. 31, 2013
ALLIANCEBERNSTEIN 908785 $22.00M Dec. 31, 2013
Millennium Management 847592 $9.82M March 31, 2013
TSP Capital Management 836342 $20.25M Dec. 31, 2013
Private Capital Advisors 822558 $12.84M June 30, 2013
Soros Fund Management 803200 $4.09M March 31, 2012
Schroder Investment Management 797175 $28.24M Sept. 30, 2013
Deutsche Bank Aktiengesellschaft 795222 $28.17M Sept. 30, 2013
PUTNAM INVESTMENTS 719474 $25.80M Sept. 30, 2013
Inves 710187 $17.19M Dec. 31, 2013
VIKING GLOBAL INVESTORS 672513 $23.83M Sept. 30, 2013
First Eagle Investment Management 665560 $10.39M June 30, 2013
MORGAN STANLEY 640556 $15.51M Dec. 31, 2013
Oxford Asset Management 635215 $3.30M June 30, 2012
Ayer Capital Management 614200 $3.13M March 31, 2012
CITADEL ADVISORS 585757 $6.78M March 31, 2013
Capital Fund Management S.A. 579746 $14.05M Dec. 31, 2013
Ameriprise Financial 573933 $13.89M Dec. 31, 2013
D. E. Shaw & Co 555383 $3.73M Dec. 31, 2012
Bennett Lawrence Management 550735 $13.33M Dec. 31, 2013

Who sold Celldex Therapeutics?

Fund Name Date Sold Number of Shares Sold Share Valuation
Barclays June 30, 2011 743716 $2.63M
UBS AG Dec. 31, 2010 668996 $2.76M